AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00701090
Drug: Comparator: glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
Trial: NCT00701090
Drug: open-label metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
Trial: NCT01576172
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01576172
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01576172
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00446524
Drug: Valsartan + Amlodipine besilate
RxNorm normalized name: amlodipine / valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
Trial: NCT01196052
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
Trial: NCT01448057
Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
Trial: NCT01448057
Drug: Paracetamol (500 mg) tablets
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (500 mg) tablets
Trial: NCT00619970
Drug: xifaxan
RxNorm normalized name: XIFAXAN
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: xifaxan 550mg TID x10days
Trial: NCT03078075
Drug: Naltrexone: Vivitrol®
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks
Trial: NCT03078075
Drug: Bupropion: Wellbutrin XL®
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion: 450 mg oral dose daily
Trial: NCT00381199
Drug: Amitriptyline Hydrochloride
RxNorm normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00381199
Drug: Nabilone
RxNorm normalized name: Nabilone
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01948336
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
Trial: NCT01948336
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.
Trial: NCT01948336
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.
Trial: NCT01984372
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.
Trial: NCT00047671
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDA Approved antidepressant
Trial: NCT00240981
Drug: Topical gel (placebo formulation)
RxNorm normalized name: Topicale
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day.
Trial: NCT02428543
Drug: Ponatinib and Cytarabine
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
Trial: NCT03331770
Drug: Latanoprost Ophthalmic Product
RxNorm normalized name: latanoprost Ophthalmic Product
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Multidose bottle, preserved with potassium sorbate, that can be stored at room temperature up to 30°C during all shelf life, the emulsion does not require shaking before use
Trial: NCT00893464
Drug: IXAZOMIB
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
Trial: NCT02989389
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01822600
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient in the intervention group received Human Albumin 20%® (ZLB Behring, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels \< 25 g/L.
Trial: NCT03542760
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care
Trial: NCT00113074
Drug: Nicotine Replacement Therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy program
Trial: NCT01822600
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up.
Trial: NCT00528580
Drug: Identical-appearing placebo
DrugBank: Pear (DB10554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily x 4 days
Trial: NCT00254956
Drug: ciclesonide (XRP1526)
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03085056
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: trametinib orally 2mg daily during each 4 week cycle
Trial: NCT03085056
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks
Trial: NCT03933956
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral empagliflozin 10mg daily for 30 days
Trial: NCT03472365
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
Trial: NCT03472365
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
Trial: NCT00486837
Drug: Alpha1-Proteinase Inhibitor (Human)
RxNorm normalized name: Alpha1-proteinase inhibitor (human)
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
Trial: NCT00516880
Drug: rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00957047
Drug: eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT01515137
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
Trial: NCT03962738
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT02582983
Drug: Enfuvirtide
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
Trial: NCT05348148
Drug: Oral Levocetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
Trial: NCT05348148
Drug: Combined Intranasal Mometasone Furoate with oral Levocetirizine
RxNorm normalized name: Mometasone Furoate
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
Trial: NCT04074174
Drug: Oral contraceptive (OC) tablets
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily on days 1-8 and days 79-86
Trial: NCT02355431
Drug: Itacitinib
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets to be administered by mouth once daily at dose selected from safety run-in phase
Trial: NCT02355431
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg tablets administered by mouth once daily at total daily dose of 150 mg
Trial: NCT00924326
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -5 to -1 (after administration of cyclophosphamide): 25 mg/m\^2 intravenous (IV) over 30 minutes
Trial: NCT00924326
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 0: 720,000 IU/kg intravenously (IV) every 8 hours for a maximum of 15 doses.
Trial: NCT00924326
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -5 to -3 (after administration of cyclophosphamide): 30 mg/m\^2 intravenous (IV) over 30 minutes
Trial: NCT02164448
Drug: the dexmedetomidine group
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
Trial: NCT02164448
Drug: the control group
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infusion from induction of anesthesia to end of surgery
Trial: NCT01155986
Drug: Lidocaine 5% medicated plaster
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical hydrogel plaster (700mg lidocaine)
Trial: NCT05348148
Drug: Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline
RxNorm normalized name: Mometasone Furoate
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
Trial: NCT00509067
Drug: Galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
Trial: NCT00509067
Drug: CDP-choline
RxNorm normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
Trial: NCT00509067
Drug: risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
Trial: NCT03394144
Drug: AZD9150, Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT
Trial: NCT00131469
Drug: Teriparatide (FORTEO)
RxNorm normalized name: TERIPARATIDE (FORTEO) 250MCG/ML (600MCG) INJ,PEN,2.4ML
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
Trial: NCT00574288
Drug: Part 1: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
Trial: NCT00574288
Drug: Part 2: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
Trial: NCT02734160
Drug: Galunisertib
RxNorm normalized name: Galunisertib
DrugBank: Galunisertib (DB11911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02734160
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT02577614
Drug: FEIBA
RxNorm normalized name: Feiba
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of FEIBA after cardiopulmonary bypass
Trial: NCT00175617
Drug: Minoxidil
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
Trial: NCT00531856
Drug: Inhaled carbon monoxide
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
Trial: NCT00531856
Drug: Inhaled carbon monoxide
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
Trial: NCT00531856
Drug: Inhaled carbon monoxide
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
Trial: NCT00531856
Drug: Inhaled Carbon Monoxide
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
Trial: NCT00531856
Drug: Inhaled Carbon Monoxide
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
Trial: NCT01479179
Drug: AMG 479
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I.
Trial: NCT03912337
Drug: Erenumab
RxNorm normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Erenumab once every 4 weeks. SC injection.
Trial: NCT01479179
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.~Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle.
Trial: NCT02871778
Drug: VX-371
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02871778
Drug: VX-371 + HS
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02871778
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01568398
Drug: TAK-438
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02134080
Drug: PF-04457845
RxNorm normalized name: PF-04457845
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04457845 will be administered orally at 4mg daily for four weeks.